Ovarian cancer https://www.sciencedirect.com/science/article/pii/S0753332223009423
It is an ongoing battle trying chemotherapy mono or combinations, different dosage and intervals due to how the body treat the drug and vice versa in order to maximizing potency yet avoiding toxicity. Quite comprehensive recent article about ovarian cancer and the potentials and challenges of various targeted drug delivery systems including the below:
"A novel peptide-drug conjugate, TH1902, is currently undergoing a phase one clinical trial in patientswith advanced solid tumors, including ovarian cancer (ClinicalTrials.gov Identifier: NCT04706962). TH1902 is a sortilin-targeted peptide-drug conjugate comprising two docetaxel molecules linked to the peptide, TH19P01, through an ester linkage [25]. SORT1 is a key scavenger receptor that plays a dual role in endocytosis and receptor trafficking, facilitating the transfer of many peptides and proteins, including proneurotrophins, from the cell surface to specific intracellular locations [14], [25]. SORT1 is associated with cancer cell proliferation, migration, and invasion, and its expression is significantly higher in ovarian cancer compared to healthy ovarian tissue. [14]. In a preclinical investigation conducted by Currie et al. (2022), TH1902 reduced ovarian cancer cell growth and induced more SORT1-dependent cell death than unconjugated docetaxel. This was a result of TH1902's potential to leverage SORT1's ligand internalization ability."